HC-T6IV
Hayflick Partners
topical rapamycin, mTOR inhibition, micro-dose delivery
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companies
topical rapamycin, mTOR inhibition, micro-dose delivery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Hayflick Partners presents itself as a development-stage company built on the belief that new discoveries in aging biology can be used to address specific health and aesthetic concerns tied to declining cellular function. It highlights rapamycin as a scientifically grounded intervention, emphasizing its efficacy across multiple clinical settings and stating that its flagship approach is a low-dose topical therapy intended to capture rapamycin's healthspan benefits while reducing systemic exposure.
Source